Skip to content

Psilocybin for depression: all studies

Page 47 of 51: studies 461 to 470 of 509, newest first. Back to the psilocybin for depression overview

Research

Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression—Quo Vadis?

JAMA Psychiatry November 4, 2020 Charles F. Reynolds 5 citations

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...

DOI: 10.1001/jamapsychiatry.2020.2901 (opens in new tab) Depression economics Otorhinolaryngology Family medicine Neurology

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

JAMA Psychiatry November 4, 2020 Mary P Cosimano, Alan K. Davis, Frederick S. Barrett et al. 1,269 citations

Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. Objective: To investigate the effect of...

DOI: 10.1001/jamapsychiatry.2020.3285 (opens in new tab) Full text (opens in new tab) Psilocybin Major depressive disorder Randomized controlled trial Context archaeology +4

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies

Acta Psychiatrica Scandinavica October 30, 2020 Kristoffer Andreas Aamodt Andersen, Robin Carhart-Harris, David Nutt et al. 352 citations

Abstract Objective To conduct a systematic review of modern‐era (post‐millennium) clinical studies assessing the therapeutic effects of serotonergic psychedelics drugs for mental health conditions. Although the main focus was on efficacy and safety, study characteristics, duration of antidepressants effects across studies, and the role of the subjective drug experiences were also reviewed and...

DOI: 10.1111/acps.13249 (opens in new tab) Psilocybin Anxiety Serotonergic Major depressive disorder +6

Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders

International Journal of Molecular Sciences September 7, 2020 Matas Vitkauskas, Ajay S. Mathuru 4 citations

Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of psychedelics for treating depressive states has emerged in the last decade as new directions to devise interventional strategies and therapies. Several clinical trials using deep brain stimulation of the habenula, or using ketamine, and psychedelics...

DOI: 10.3390/ijms21186525 (opens in new tab) Psilocybin Serotonergic Habenula Neuroimaging +6

Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials

Biomedicines September 5, 2020 Ana Sofia Vargas, Ângelo Luís, Mário Barroso et al. 121 citations

Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. The aim of this work was to perform a systematic review with meta-analysis of clinical trials to assess the therapeutic effects and safety of psilocybin on those...

DOI: 10.3390/biomedicines8090331 (opens in new tab) Psilocybin Anxiety Context archaeology Beck depression inventory +6

Psychedelic science in post-COVID-19 psychiatry

Irish Journal of Psychological Medicine August 19, 2020 John R. Kelly, Matthew Crockett, Laith Alexander et al. 16 citations

The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising...

DOI: 10.1017/ipm.2020.94 (opens in new tab) Full text (opens in new tab) Psilocybin Major depressive disorder Hallucinogen Mental health +2

The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)

August 13, 2020 Jeffrey Guss, Robert Krause, Jordan Sloshower 86 citations preprint

The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therapeutic framework for...

DOI: 10.31234/osf.io/u6v9y (opens in new tab) Full text (opens in new tab) Psychedelic therapy Major depressive disorder Mdd Psilocybin-assisted therapy +9

Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms

August 5, 2020 Sofia Beck 1 citation

Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward how we treat these psychiatric disorders.

DOI: 10.33015/dominican.edu/2020.pas.10 (opens in new tab) Psilocybin Anxiety Depression economics Affect linguistics +3